Ventyx Biosciences (VTYX) Competitors $2.02 -0.05 (-2.42%) Closing price 04:00 PM EasternExtended Trading$2.10 +0.09 (+4.21%) As of 04:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VTYX vs. DAWN, GHRS, SION, STOK, CDXC, XNCR, KALV, EOLS, SANA, and UPBShould you be buying Ventyx Biosciences stock or one of its competitors? The main competitors of Ventyx Biosciences include Day One Biopharmaceuticals (DAWN), GH Research (GHRS), Sionna Therapeutics (SION), Stoke Therapeutics (STOK), ChromaDex (CDXC), Xencor (XNCR), KalVista Pharmaceuticals (KALV), Evolus (EOLS), Sana Biotechnology (SANA), and Upstream Bio (UPB). These companies are all part of the "pharmaceutical products" industry. Ventyx Biosciences vs. Its Competitors Day One Biopharmaceuticals GH Research Sionna Therapeutics Stoke Therapeutics ChromaDex Xencor KalVista Pharmaceuticals Evolus Sana Biotechnology Upstream Bio Ventyx Biosciences (NASDAQ:VTYX) and Day One Biopharmaceuticals (NASDAQ:DAWN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, valuation, earnings, risk and dividends. Which has more risk & volatility, VTYX or DAWN? Ventyx Biosciences has a beta of 0.93, meaning that its share price is 7% less volatile than the S&P 500. Comparatively, Day One Biopharmaceuticals has a beta of -1.27, meaning that its share price is 227% less volatile than the S&P 500. Do analysts rate VTYX or DAWN? Ventyx Biosciences currently has a consensus price target of $10.00, indicating a potential upside of 395.05%. Day One Biopharmaceuticals has a consensus price target of $30.57, indicating a potential upside of 354.26%. Given Ventyx Biosciences' higher possible upside, equities research analysts plainly believe Ventyx Biosciences is more favorable than Day One Biopharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ventyx Biosciences 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Day One Biopharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Which has better valuation & earnings, VTYX or DAWN? Day One Biopharmaceuticals has higher revenue and earnings than Ventyx Biosciences. Day One Biopharmaceuticals is trading at a lower price-to-earnings ratio than Ventyx Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVentyx BiosciencesN/AN/A-$135.12M-$1.75-1.15Day One Biopharmaceuticals$131.16M5.20-$95.50M-$0.71-9.48 Do institutionals and insiders believe in VTYX or DAWN? 97.9% of Ventyx Biosciences shares are held by institutional investors. Comparatively, 88.0% of Day One Biopharmaceuticals shares are held by institutional investors. 18.2% of Ventyx Biosciences shares are held by company insiders. Comparatively, 6.2% of Day One Biopharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is VTYX or DAWN more profitable? Ventyx Biosciences has a net margin of 0.00% compared to Day One Biopharmaceuticals' net margin of -42.66%. Day One Biopharmaceuticals' return on equity of -14.98% beat Ventyx Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Ventyx BiosciencesN/A -47.45% -43.49% Day One Biopharmaceuticals -42.66%-14.98%-13.04% Does the media refer more to VTYX or DAWN? In the previous week, Day One Biopharmaceuticals had 1 more articles in the media than Ventyx Biosciences. MarketBeat recorded 1 mentions for Day One Biopharmaceuticals and 0 mentions for Ventyx Biosciences. Ventyx Biosciences' average media sentiment score of 1.87 beat Day One Biopharmaceuticals' score of 0.93 indicating that Ventyx Biosciences is being referred to more favorably in the media. Company Overall Sentiment Ventyx Biosciences Very Positive Day One Biopharmaceuticals Positive SummaryDay One Biopharmaceuticals beats Ventyx Biosciences on 9 of the 16 factors compared between the two stocks. Get Ventyx Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for VTYX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VTYX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VTYX vs. The Competition Export to ExcelMetricVentyx BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$143.74M$2.90B$5.49B$8.94BDividend YieldN/A2.69%5.38%4.13%P/E Ratio-1.1521.3126.2119.90Price / SalesN/A277.38415.20165.00Price / CashN/A41.8936.4957.06Price / Book0.567.518.055.38Net Income-$135.12M-$55.05M$3.15B$248.50M7 Day Performance-15.83%2.44%1.93%2.99%1 Month Performance-0.98%7.32%4.91%6.03%1 Year Performance-5.61%5.38%35.87%20.40% Ventyx Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VTYXVentyx Biosciences3.1421 of 5 stars$2.02-2.4%$10.00+395.0%-8.4%$143.74MN/A-1.1530DAWNDay One Biopharmaceuticals2.1324 of 5 stars$6.48+2.5%$30.57+371.8%-51.3%$640.61M$131.16M-9.1360Upcoming EarningsGHRSGH Research1.6225 of 5 stars$11.68-5.1%$32.00+174.0%+8.3%$640.47MN/A-14.7810SIONSionna TherapeuticsN/A$14.10-2.7%$38.50+173.0%N/A$639.36MN/A0.0035News CoveragePositive NewsInsider TradeGap UpSTOKStoke Therapeutics4.0143 of 5 stars$11.59+0.1%$23.20+100.2%-16.0%$632.23M$36.56M14.67100Analyst ForecastCDXCChromaDex3.1679 of 5 starsN/A$9.03+∞N/A$611.50M$99.60M787.29120XNCRXencor4.0365 of 5 stars$8.41-1.5%$28.00+232.9%-57.6%$607.80M$110.49M-2.75280KALVKalVista Pharmaceuticals4.2768 of 5 stars$11.93-1.8%$24.83+108.2%-2.5%$604.04MN/A-3.21100EOLSEvolus4.0693 of 5 stars$9.38+1.1%$23.75+153.2%-17.0%$598.33M$266.27M-10.54170SANASana Biotechnology2.5339 of 5 stars$2.60-0.4%$10.80+315.4%-48.3%$588.49MN/A-2.95380High Trading VolumeUPBUpstream Bio1.8387 of 5 stars$10.72-1.5%$56.50+427.1%N/A$585.28M$2.37M0.0038 Related Companies and Tools Related Companies Day One Biopharmaceuticals Competitors GH Research Competitors Sionna Therapeutics Competitors Stoke Therapeutics Competitors ChromaDex Competitors Xencor Competitors KalVista Pharmaceuticals Competitors Evolus Competitors Sana Biotechnology Competitors Upstream Bio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VTYX) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe $100 Trillion AI Story No One Is Telling YouJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | SponsoredSomething very strange is happening...What a "Mar-a-Lago Accord" could mean for the U.S. dollar While protests dominate the news... hardly anyone...Stansberry Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ventyx Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ventyx Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VTYX Stock Alerts